



Integra LifeSciences Announces the Launch of its New CUSA® Clarity Ultrasonic Tissue Ablation Platform in Japan

August 15, 2018

Tokyo, Japan, July 23, 2018 - [Integra LifeSciences Holdings Corporation](#) (Nasdaq:[IART](#)), a global leader in medical technology, announces the launch of its new CUSA® Clarity ultrasonic tissue ablation platform in Japan. The system was launched in North America and Europe and has gained significant adoption since its introduction a year ago.

This next generation ultrasonic tissue ablation system is designed to help neurosurgeons remove fibrous tissue more quickly and with greater precision. CUSA Clarity is a much-awaited addition to Integra's Codman Specialty Surgical neurosurgery portfolio in Japan and is anticipated to drive CUSA penetration in the local neurosurgery market.

A photo accompanying this announcement is available at www.investor.integralife.com

Integra's CUSA Clarity was engineered to maximize surgical performance for surgeons, staff and patients through a system that provides power, precision and comfort for complex neurosurgery. The unique CUSA Clarity system is the only ultrasonic tissue ablation system that combines a tough tissue tip, continuous tissue contact, a precision and ergonomic hand piece, and adaptive power all in one system. These four integrated components provide an increase in the fibrous tissue removal over the CUSA® Excel+ system.

The next generation CUSA Clarity also features a sleek new console design with an intuitive touchscreen and CUSA Quick Connect™ cartridge and tubing set to streamline operating room setup and workflow.

"I could selectively remove more tumor than usual in particular around the complex thalamus area," said Dr. Maruyama, chief surgeon specializing in glioma surgery at Tokyo Women's Medical University. "CUSA Clarity with Tissue Select feature provides the right control, while operating near critical structures, because it allows me to feel a difference when the tip is in contact with low strength tissue versus a high strength tissue.

"In combination with ISOCOOL® Bipolar Forceps, I can perform minimally invasive procedures for glioma. Operating room staff were impressed by the intuitive and easy setup, which is quite important for readiness when you need it."

The CUSA Clarity was developed with extensive feedback from over 150 touchpoints worldwide. It has been commercialized successfully in North America, Europe, and Australia. For more information and further indications for use, visit our [website](#).

About Integra

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel[®], Bactiseal[®], Cadence[®], Certas[™], Codman[®], CUSA[®], DuraGen[®], DuraSeal[®], ICP Express[®], Integra[®], MediHoney[®], MicroFrance[®], PriMatrix[®], Salto Talaris[®], SurgiMend[®], TCC-EZ[®], Titan[™] and VersaTru[™]. For the latest news and information about Integra and its brands, please visit www.integralife.com.

CONTACT:

Integra LifeSciences Holdings Corporation

Investors

Sravan Emany
Vice President, Treasurer & Investor Relations
+1 609-936-2488

Michael Beaulieu
+1 609-750-2827
michael.beaulieu@integralife.com

Media

Marie-Anne Girel
+33 437 475 900
marie-anne.girel@integralife.com
Integra Japan株式会社
〒107-0052 東京都港区赤坂7-9-4
AKASAKA Vetoro 4F Fax: 03-6809-0236
Tel: 03-6809-0235